PBMC gene expression from Crohn's disease patients before Infliximab therapy.

About 40% IBD patients treated with anti-TNF antibodies do not respond to therapy. Baseline biomarkers of response are therefore of interest. By combining computational deconvolution of gene expression and meta-analysis approaches we identified cellular biomarkers in tissue (validated in 2 cohorts by IHC of biopsies), and investigated associated gene biomarkers in blood. This dataset provides data from the validation cohort III (blood). Whole blood samples were collected from 22 patients diagnosed with Crohn's disease, just before starting anti-TNF therapy (Infliximab). All patients were naive to anti-TNF. Response to therapy was assessed after 14 weeks based on changes in CRP and Calprotectin, as well as endoscopy (Responders: 17; Non-responders: 5). The prognostic power of genes identified to be related to cellular biomarkers identified from meta-analysis of public datasets of biopsy tissues were investigated.

约40%接受抗TNF抗体治疗的炎症性肠病（Inflammatory Bowel Disease, IBD）患者无治疗应答，因此治疗应答的基线生物标志物成为研究热点。本研究结合基因表达计算反卷积与荟萃分析方法，在组织中鉴定出细胞生物标志物（该结果已通过2个队列的活检组织免疫组化（Immunohistochemistry, IHC）验证），并对血液中的相关基因生物标志物展开了探究。本数据集包含验证队列III（血液样本）的相关实验数据。研究纳入22名确诊克罗恩病的抗TNF初治患者，在其即将接受英夫利昔单抗（Infliximab）抗TNF治疗前采集全血样本。治疗14周后，通过C反应蛋白（C-reactive protein, CRP）、钙卫蛋白水平变化及内镜检查结果评估治疗应答情况，其中应答者17例，无应答者5例。本研究还针对从公共活检组织数据集的荟萃分析中鉴定出的细胞生物标志物相关基因的预后效能进行了探究。